Fund moves
3.9%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SLN · NASDAQ · Pharmaceutical Preparations
Silence Therapeutics (SLN) · oqro.io/stocks/SLN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$19.81+0.00 (0.00%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Silence Therapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of Silence Therapeutics (SLN) was filed with the SEC in the last 90 days.
No trade in Silence Therapeutics (SLN) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+212.0% (+$13.46) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $6.35 on Nov 20, 2025 to $19.81 on Nov 20, 2026 (+212.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in London.
Last 12 months
+212.0%
Market value
$3.7B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.42M shares sold short (1.3% of shares outstanding), −17.4% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$559K
−98.7% vs the year before
Net income, fiscal 2025
−$88.6M
A loss for the year
Shares outstanding
187M
As of Sep 30, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest annual report filed Mar 5, 2026, compared with the one filed Feb 27, 2025. Read the filing
From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. We do not currently have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on our results of operations, financial condition or cash flows.
Source: SEC EDGAR, Form 10-K filed Mar 5, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
FMR LLC
13G · passive · Crossed 5% · 13.2M shares · filed Nov 5, 2026
Tetragon Financial Group Limited
13G · passive · Up from 5.2% · 9.88M shares · filed Oct 13, 2026
Recent moves
TCG Crossover GP I, LLC fell below 5% (3.9%) · Schedule 13G, 2026
Raymond Debbane fell below 5% (4.6%) · Schedule 13G, 2026
FMR LLC went above 5%, with 7.1% · Schedule 13G, 2026
Tetragon Financial Group Limited raised its stake to 5.3% from 5.2% · Schedule 13G, 2026
Tetragon Financial Group Limited went above 5%, with 5.2% · Schedule 13G, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Deals
Things to keep in mind
Revenue
$0
−100.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$44.1M
This quarter −$12.8M, a year earlier −$10.9M
Net debt
—
Debt —, cash $248M, at Sep 30, 2026
Net income, last 12 months
−$51.4M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Revenue and earnings history, 4 fiscal yearsEarnings dates and the stock's moves
Fails to deliver: 185K shares (about $1.73M) were not delivered on time for settlement on Oct 16, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 48.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (27.2% on ATS, 21.1% with other brokers), close to its 26-week average of 46.7%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (14.6%), INTELLIGENT CROSS LLC (11.5%), SIGMA X2 (7.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Top officer leaving
“On December 15, 2025, Silence Therapeutics plc (the “Company”) announced that Craig Tooman, who has served as the Company’s President, Chief Executive Officer and a member of the Company’s Board of Directors (the “Board”) since 2022, agreed by mutual consent to end his employment with the Company and step down from the Board effective December 14, 2025 (the “Effective Date”).”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in polycythemia vera.
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 5, 2026. Read the filing
−99% on the year before ($43.1M)
$144K the year before
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
We are a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Our siRNA molecules are designed to harness the body’s natural mechanism of RNAi by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. By degrading the message that encodes the disease-associated protein, the production of that protein is reduced and its level of activity is lowered. In the field of RNAi therapeutics, this reduction of disease-associated protein production and activity is referred to as “gene silencing.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
On the public record for Silence Therapeutics over the 12 months to Nov 21, 2026: 1 clinical trial.